BioPharma Credit Plc (LSE: BPCR), has entered into a definitive senior secured note purchase agreement for issuance and sale by OptiNose US, Inc, a wholly-owned subsidiary of OptiNose along with BioPharma Credit Investments V LP, Inc. The agreement is for the sale of senior secured notes in an aggregate original principal amount of up to US$150 million. The company will initially invest US$44.0 million, and the company's share of the transaction will be up to US$82.5 million.
On 13th September 2019, at the time of writing, GMT 08:04 AM, BPCR shares were trading at GBX 1.02, down by 0.005 points or 0.49% against the previous day closing price.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.